Articles tagged with Breast Cancer
A new study found that women with disabilities are less likely to participate in breast and bowel cancer screenings due to practical barriers. Women with multiple disabilities or those without access to a car were particularly affected.
Researchers have developed a new software tool that reveals molecular connections between breast cancer tumor cells and immune system cells in the bloodstream. The study found that these connections vary depending on the type of breast cancer, potentially leading to new treatment and monitoring strategies.
Researchers at Trinity College Dublin found that rogue messengers released by cancer cells can suppress the body's immune system, making it harder to fight cancer. The discovery may lead to a blood test to identify patients most susceptible to treatment resistance, allowing for personalized treatment options.
Julie Palmer, a BU researcher, was awarded for her work on breast cancer disparities. She aims to reduce mortality by identifying factors that influence hormone receptor negative breast cancer.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is a randomized trial comparing two types of digital mammography for breast cancer screening. The study aims to determine if the newer technology, tomosynthesis (3D), reduces advanced breast cancers more effectively than conventional mammography.
Researchers have discovered a powerful combination treatment that disrupts multiple factors in aggressive triple-negative breast cancer. The novel approach, combining a protein inhibitor with a chemotherapy drug, produced a synergistic effect that was more effective than either drug alone.
A study by NYU Langone Health found that a higher-dose, shorter form of radiation is safe and effective for breast cancer patients under 50, with no increased risk of late side effects. The new technique also yields good to excellent long-term cosmetic results in 92% of patients.
A survey of breast cancer clinic patients found that short- and long-term side effects were often better than anticipated, with 83% and 84% of respondents reporting similar expectations. Women reported lower fears and more positive experiences after treatment, highlighting the need to address misconceptions about radiation therapy.
Researchers found significant differences in tumor infiltrating lymphocyte count between African-American and European-American women with triple negative breast cancer. Higher counts of TILs were associated with better survival in early-stage African-American TNBC patients, suggesting a potential prognostic biomarker.
Researchers at Case Western Reserve University have developed a new MRI contrast agent that can pinpoint breast cancers at early stages and distinguish between aggressive and slow-growing types. The agent is more efficient, safer, and easier to flush from the body than traditional agents.
A new study found that smoking at the time of diagnosis and changes in smoking within five years after diagnosis are associated with long-term breast cancer mortality. Quitting smoking after diagnosis may improve survival among women with breast cancer, but continued smoking increases risk of death.
A new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. The labyrinth chip is already in use in a breast cancer clinical trial, enabling doctors to plan customized treatments and monitor genetic changes.
Researchers at Virginia Tech Carilion Research Institute have successfully determined the full architecture of the BRCA1 protein, a key player in breast cancer susceptibility. By restoring its structural normalcy, they identified a potential route to revive the protein's cancer-fighting abilities.
A modified poliovirus therapy has been found to induce an inflammation process that counteracts cancer cells' ability to evade the immune system. The therapy activates dendritic cells and macrophages, which present tumor antigens to T-cells, launching a targeted immune response.
A groundbreaking collaboration has been awarded $2.5 million to explore an innovative new treatment path for breast and prostate cancer. The project aims to 'reprogram' hormone receptors, potentially transforming the lives of those affected by these cancers.
Professor Cuzick received the Cancer Research UK Lifetime Achievement Award for his pioneering work on cancer prevention, including developing effective breast cancer treatments and models to assess risk. The award recognizes his exceptional contributions to the field of cancer research spanning over 30 years.
A pilot study of 87 female breast cancer survivors found that increased physical activity more than doubled their post-treatment mental processing speed. The intervention program tailored to each person's interests and abilities improved cognitive processing speed and some improvements in perceived mental abilities.
A recent study published in the American Journal of Roentgenology found that MRI had a 98% sensitivity rate in detecting postpartum breast cancers, leading to changes in surgical management for 28% of patients. The study also highlighted the importance of preoperative planning in managing these aggressive cancers.
A study published in Medical Care found that fewer than 20% of US women are aware of the risks of overdiagnosis and overtreatment from breast cancer screening. Women's perceptions of these risks are often negative, with those who have recently had a mammogram being particularly unconvinced.
A Chinese study found that women with visceral fat (around internal organs) are at higher risk for developing ER- breast cancer, while those with subcutaneous fat are more likely to develop ER+ breast cancer. The study's findings suggest a complex link between breast cancer and obesity.
Scientists at the University of Freiburg have developed a new model to isolate and study cancer stem cells from breast cancer patients. The team found that inhibiting the epigenetic regulator KDM4 can block proliferation of cancer stem cells, induce changes in their molecular make-up, and reduce tumor growth.
Researchers led by Mauro Ferrari, Ph.D., develop injectable nanoparticle generator polymeric doxorubicin (iNPG-pDox) to target cancer cells in lungs and liver with limited toxicity. The therapy aims to improve long-term survival and quality of life for triple-negative breast cancer patients.
A study published in JAMA Surgery found that attending surgeons can significantly influence patients' decisions to undergo contralateral prophylactic mastectomy (CPM) after a breast cancer diagnosis. The researchers surveyed over 7,800 women with stages 0-2 breast cancer and their attending surgeons, finding that surgeons' attitudes to...
A genetic study suggests that existing immunotherapy drugs could help some breast cancer patients with specific genetic changes in their tumors. The research identified a particular group of breast cancer patients who have genetic mutations that occur due to an abnormal DNA repair mechanism.
A new study published in JAMA Surgery found that surgeons played a major role in determining whether patients receive aggressive breast cancer surgery. The study revealed that surgeons' attitudes towards breast conservation and CPM had a significant impact on the likelihood of patients receiving this procedure.
A study at ESMO 2017 found that positive randomised controlled trials are twice as likely to be reported in the lay press as those with negative trials. The study also found that trials on immunotherapy and targeted therapy were more commonly reported than those on chemotherapy.
At ESMO 2017, researchers presented 55 late-breaking abstracts and 1,736 selected abstracts, featuring breakthrough treatments for various cancers. The Congress emphasized the importance of preventing cancer through lifestyle changes and explored sustainable treatment options.
Female cancer survivors face increased risks of preterm birth and small for gestational age infants after diagnosis. Certain cancers, such as cervical, breast, leukemia, brain cancer, and extranodal non-Hodgkin lymphoma, are linked to poorer pregnancy outcomes.
A study published at ESMO 2017 Congress found that abdominal fat distribution is a significant predictor of cancer diagnosis in postmenopausal women. The study, which included 5,855 women, showed that the ratio of abdominal to peripheral fat was an independent risk factor for certain cancers.
The MONARCH 3 trial showed that adding abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone. Around one-third of women may not need a CDK 4/6 inhibitor as initial treatment.
The LORELEI trial found that adding taselisib to letrozole before surgery improved outcomes for patients with early breast cancer. Taselisib showed a significant increase in objective response rate and worked particularly well in patients with PIK3CA mutant cancer cells.
A study investigated the work ability of young adult cancer survivors, finding that low education, female sex, lymphoedema, fatigue, depression, and reduced physical quality of life are associated with reduced work ability. Treatment intensity was not significantly related to work ability.
A study published in Cancer Research found that serum from women with breast cancer after exercise reduces breast cancer cell viability and tumor growth via activation of the Hippo signaling pathway. The effects were most pronounced on hormone receptor-positive breast cancer cells.
A study by London School of Hygiene & Tropical Medicine found that alcohol industry organisations distort information on cancer risk, particularly for breast and colorectal cancers. The researchers call for policymakers to reconsider relationships with these bodies, which develop alcohol policy and disseminate health info.
A team of scientists at UT Austin has developed a handheld instrument that rapidly and accurately diagnoses cancerous tissue during surgery. The MasSpec Pen is over 96% accurate and can detect cancer in marginal regions, potentially improving treatment and reducing recurrence rates.
A University of Colorado study found that blood tumor markers can predict lung cancer progression, allowing for earlier adjustments to treatment plans. Markers were associated with a 10% or greater rise in 53% of patients experiencing cancer progression, but not limited brain progression cases.
A recent study found that nearly one in four small tumours were aggressive and patients benefited from chemotherapy. Researchers identified a 70-gene signature to detect aggressive tumours.
This review indicates that adipose tissue can affect cancer development through various mechanisms, including inflammation, cell metabolism, and immune clearance. The study found that different types of fat have distinct effects on cancer cells, with some types promoting tumor growth and others inhibiting it.
A new study found a significant association between opioid use and non-adherence to hormone therapy among breast cancer patients. The study highlights the challenges of managing chronic pain in cancer survivors, who often face 10 years of treatment.
Researchers at UT Health San Antonio have developed a new, first-in-class agent called ERX-11 that blocks the growth of estrogen receptor-positive (ER-positive) breast cancer in its tracks. The new drug has shown promising results in preclinical studies and is expected to begin human trials soon.
Researchers found that Z-endoxifen provided substantial drug exposure, acceptable toxicity, and promising anti-tumor activity in patients with metastatic breast cancer who had progressed on standard anti-estrogen treatments. The treatment resulted in tumor shrinkage, with some cases lasting over two years without disease progression.
A two-stage approach to risk-reducing mastectomy, involving initial breast reduction and
Researchers have found that women with a history of preeclampsia have a 90% decrease in breast cancer risk if they carry a specific common gene variant. The study, conducted in the California Teachers Study, confirms earlier findings and aims to develop new breast cancer prevention strategies for all women.
A 14-year study found that statins reduce breast cancer risk by 45% and mortality risk by 40%. Women with high cholesterol had significantly lower breast cancer rates and improved survival rates compared to those without high cholesterol.
Researchers found that concurrent administration of anti-OX40 and anti-PD1 antibodies attenuated the effect of anti-OX40, resulting in poor treatment outcomes in mice. Sequential treatment with anti-OX40 followed by anti-PD1 improved therapeutic efficacy in some cases.
A new Yale University study reveals that women undergoing IVF to become pregnant report a more intense bodily experience compared to those donating eggs for money. Researchers found a direct correlation between the intensity of bodily experiences and the motivation for harvesting eggs.
Researchers will study a nanoparticle-based therapeutic that targets the body's own cancer immunity cycle, aiming to prevent tumor progression and metastasis. The therapy shows promise in treating melanomas, ovarian, and breast tumors, with sustainable immune stimulation and prevention of relapse.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have developed a proof-of-concept nanosystem that dramatically improves the visualization of tumors, achieving a five-fold increase over existing methods. The novel approach generates bright tumor signals by delivering quantum dots to cancer cells without toxic effects.
A study found that patients with one normal BRCA gene and germline mutations in breast and ovarian cancers had better survival rates when treated with chemotherapy. The research team evaluated the genetic profiles of 160 tumors and discovered a relationship between BRCA gene retention and resistance to treatment. Patients with normal B...
A comprehensive review highlights the importance of lifestyle modifications and emerging approaches to manage menopausal symptoms after breast cancer. Non-pharmacologic therapies and several promising emerging agents show promise for symptom relief with reduced breast cancer risk.
A study has identified a genetic signature linked to defects in the DNA damage repair-genes BRCA1 and BRCA2 in breast cancer. The researchers found that this signature is not exclusive to BRCA mutations but also indicates other ways of deactivating the DNA repair mechanism, offering new insights into breast cancer treatment decisions.
Researchers have developed and validated a nomogram that can predict overall survival and progression-free survival for patients with oropharyngeal squamous cell carcinoma treated with radiation-based therapy. The nomograms were derived from clinical trials NRG Oncology/RTOG 0129 and 0522.
A new study found that annual screening starting at age 40 reduces breast cancer-specific deaths by nearly 40%, compared to 23-31% reductions with other recommendations. The findings suggest that women starting annual mammography at age 40 may benefit from a significant reduction in breast cancer-related deaths.
Researchers found that claudin-low triple negative breast cancers have high levels of regulatory T-cells, which suppress the immune system's defenses. They developed a strategy to deplete these cells, combining it with checkpoint inhibitors to slow tumor growth and improve outcomes.
A recent study found that tumor-infiltrating immune cells, specifically regulatory T cells (Tregs), can interfere with immune-targeting therapies in aggressive breast cancers. Depleting Tregs delayed tumor growth in mouse models, suggesting a potential strategy to improve targeted treatments.
Despite high-risk genetic mutations detectable through simple blood or saliva tests, only 15% of affected women in US have taken recommended genetic test. A new study from UCLA Fielding School of Public Health highlights a significant unmet need for genetic testing across the country.
A large long-term study found that women who live in areas with high levels of outdoor light at night may be at higher risk for breast cancer. The link was stronger among women who worked night shifts and were premenopausal or current/past smokers.
A new blood test developed by Johns Hopkins Medicine accurately identifies more than half of people with early-stage colorectal, breast, lung, and ovarian cancers. The test distinguishes between cancer-specific DNA and altered DNA that can be mistaken for biomarkers.
Researchers at Dana-Farber Cancer Institute discover that CDK4/6 inhibitors not only halt cancer cell division but also spur the immune system to attack and kill cancer cells. The findings suggest that combining these drugs with immunotherapies may lead to greater anti-cancer effects.
Researchers developed a DNA sequencing-based method to detect early stage cancers by analyzing circulating tumor DNA in blood plasma. The approach, called TEC-Seq, identified cancer driver genes in over 90% of patients with colorectal, ovarian, lung, and breast cancers.